advertisement
11.3.4 Betablocker (13)
Showing records 1 to 13
Display all abstracts in classification 11.3.4 Betablocker
Search within classification 11.3.4 Betablocker25386 Inhibition and activation of carbonic anhydrase I and II activities by effective ocular hypotensive agents (timolol and latanoprost)
Hirose J; Hata T; Ono Y
Journal of Biological Inorganic Chemistry 2009; 14: S194-S195
25376 Timolol activates the enzyme activities of human carbonic anhydrase I and II
Sugimoto A; Ikeda H; Tsukamoto H; Kihira K; Ishioka M; Hirose J; Hata T; Fujioka H; Ono Y
Biological & Pharmaceutical Bulletin 2010; 33: 301-306
25165 Experimental model of ocular hypertension in the rat: study of the optic nerve capillaries and action of hypotensive drugs
Díaz F; Villena A; Vidal L; Moreno M; García-Campos J; Pérez de Vargas I
Investigative Ophthalmology and Visual Science 2010; 51: 946-951
25457 Effects of brinzolamide vs timolol as an adjunctive medication to latanoprost on circadian intraocular pressure control in primary open-angle glaucoma Japanese patients
Ishikawa M; Yoshitomi T
Clinical Ophthalmology 2009; 3: 493-500
25615 Ocular blood flow and oxygen delivery to the retina in primary open-angle glaucoma patients: The addition of dorzolamide to timolol monotherapy
Siesky B; Harris A; Kagemann L; Stefansson E; McCranor L; Miller B; Bwatwa J; Regev G; Ehrlich R
Acta Ophthalmologica 2010; 88: 142-149
25207 Effect of dorzolamide and timolol on ocular pressure: blood flow relationship in patients with primary open-angle glaucoma and ocular hypertension
Fuchsjäger-Mayrl G; Georgopoulos M; Hommer A; Weigert G; Pemp B; Vass C; Garhöfer G; Schmetterer L
Investigative Ophthalmology and Visual Science 2010; 51: 1289-1296
25305 Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: A prospective, randomized, double-masked, active-controlled, thr
Sonty S; Mundorf T K; Stewart J A; Stewart W C
Clinical Therapeutics 2009; 31: 2063-2071
25126 Is the medication used to achieve the target intraocular pressure in glaucoma therapy of relevance?--an exemplary analysis on the basis of two beta-blockers
Grieshaber MC; Flammer J
Progress in Retinal and Eye Research 2010; 29: 79-93
25418 Effects of timolol and latanoprost on respiratory and cardiovascular status in elderly patients with glaucoma
Ergin A; Ornek K; Gullu R; Bulcun E; Ekici M; Ekici A
Journal of Ocular Pharmacology and Therapeutics 2009; 25: 463-466
25063 Using diurnal intraocular pressure fluctuation to assess the efficacy of fixed-combination latanoprost/timolol versus lantanoprost or timolol monotherapy
Varma R Md Mph; Hwang LJ Phd; Grunden JW Pharmd; Bean GW Bs
British Journal of Ophthalmology 2010; 94: 80-84
25067 Fixed Combination of Latanoprost and Timolol vs Individual Components for Primary Open-Angle Glaucoma or Ocular Hypertension: A Randomized, Double-Masked Study
Higginbotham EJ; Olander KW; Kim EE; Grunden JW; Kwok KK; Tressler
Archives of Ophthalmology 2010; 128: 165-172
25420 Comparative study of topical application of timolol and verapamil in patients with glaucoma within 6 months
Shayegan M R; Boloorian A A; Kianoush S
Journal of Ocular Pharmacology and Therapeutics 2009; 25: 551-553
25328 Designing dendrimers for ocular drug delivery
Spataro G; Malecaze F; Turrin C -O; Soler V; Duhayon C; Elena P -P; Majoral J -P; Caminade A -M
European Journal of Medicinal Chemistry 2010; 45: 326-334
